Canaccord analyst Edward Nash raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $428 from $420 and keeps a Buy rating on the shares. The firm said they reported financial results and business highlights for 2Q25. Product sales revenue for Rezdiffra during the quarter was $212.8M, representing 55% sequential growth. The actual 2Q revenue beat the firm’s estimate and consensus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Strong Q2 2025 Results
- Madrigal Pharmaceuticals reports Q2 EPS ($1.90), consensus ($3.53)
- MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Madrigal Pharmaceuticals Signs Global License Agreement
- Madrigal Pharmaceuticals enters license pact with CSPC for SYH2086